MannKind Corporation (MNKD) - Halal (Shariah-Compliant)
MannKind Corporation (MNKD) is classified as Halal (Shariah-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
- Sector
- Healthcare
- Industry
- Biotechnology
- Result
- Pass
- Reason
- The sector "Healthcare" and industry "Biotechnology" are not in the excluded categories.
Financial Ratios
- Debt Ratio
- Value: 18.1% | Threshold: 30% | Result: Pass
- Cash & Interest-bearing Securities Ratio
- Value: 6.1% | Threshold: 30% | Result: Pass
- Non-Permissible Income Ratio
- Value: 2.3% | Threshold: 5% | Result: Pass
Dividend Purification
Purification percentage: 2.31%.Based on the company's financial statements, approximately 2.31% of dividend income should be donated to charity for purification. This is derived from identified interest income (2.31% of total income). Some scholars may differ on the exact calculation method.
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.